TriSalus Life Sciences (TLSI) Preferred Stock Liabilities (2020 - 2023)

TriSalus Life Sciences has reported Preferred Stock Liabilities for 4 years, with the latest figure at $12.0 million in Q2 2023.

• For the quarter ending Q2 2023, Preferred Stock Liabilities fell 95.18% year-over-year to $12.0 million; the trailing twelve-month figure through Jun 2023 stood at $12.0 million (down 95.18% YoY), and the FY2022 full-year result was $164.0 million, up 2.18% from the prior year.
• Preferred Stock Liabilities for Q2 2023 stood at $12.0 million, down from $20.2 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $250.0 million in Q2 2022, with the low at $12.0 million in Q2 2023.
• Historically, Preferred Stock Liabilities has averaged $183.7 million across 4 years, with a median of $250.0 million in 2020.
• Annual changes were most pronounced in 2022 — Preferred Stock Liabilities grew 2.18% — and 2023, when it slumped 95.18%.
• TriSalus Life Sciences' Preferred Stock Liabilities stood at $250.0 million in 2020, then sank by 35.8% to $160.5 million in 2021, then increased by 2.18% to $164.0 million in 2022, then plunged by 92.66% to $12.0 million in 2023.
• The last three Preferred Stock Liabilities figures came in at $12.0 million (Q2 2023), $20.2 million (Q1 2023), and $164.0 million (Q4 2022), per Business Quant data.